Characteristics | Discovery set (n = 47) | Validation set (n = 16) | ||||
---|---|---|---|---|---|---|
NPC patients (n = 22) | healthy controls (n = 25) | p value | NPC patients (n = 8) | healthy controls (n = 8) | p value | |
Median age (y, range) | 48 (25–68) | 45 (25–65) | 0.933 | 50 (20–69) | 46 (26–61) | 0.311 |
Gender | 0.756 | 0.619 | ||||
Male | 14 (63.6%) | 16 (64.0%) | 6 (75%) | 5 (62.5%) | ||
Female | 8 (36.4%) | 9 (36.0%) | 2 (25%) | 3 (37.5%) | ||
Smoking | 0.713 | 0.642 | ||||
Yes | 10 (45.5%) | 10 (40.0%) | 4 (50%) | 5 (62.5%) | ||
No | 12 (54.5%) | 15 (60.0%) | 4 (50%) | 3 (37.5%) | ||
Drinking | 0.825 | 0.334 | ||||
Yes | 3 (13.6%) | 4 (16.0%) | 1 (12.5%) | 0 | ||
No | 19 (86.4%) | 21 (84.0%) | 7 (87.5%) | 8 (100%) | ||
Karnofsky performance score | 0.129 | 0.334 | ||||
≤ 80 | 2 (9.1%) | 0 | 1 (12.5%) | 0 | ||
≥ 90 | 20 (90.9%) | 25 (100/%) | 7 (87.5%) | 8 (100%) | ||
Pathology (WHO classification) | ||||||
Non-keratinizing (typeII-III) | 22 (100.0%) | 8 (100.0%) | ||||
Pre-EBV DNA (copies/mL) Median (rang) | 1,597,817 (0–59,200,000) | 0 | 0.001 | 1,959,159 (0–2,860,000) | 0 | 0.022 |
LDH (U/L) Median (range) | 168 (102–684) | 115 (101–298) | 0.368 | 171 (116–339) | 137 (102–274) | 0.119 |
HGB(g/L) Median (range) | 127 (81–169) | 135 (121–168) | 0.289 | 130 (93–172) | 129 (117–148) | 0.085 |
ALB(g/L) Median (range) | 41.3 (30–55) | 46 (37–56) | 0.041 | 41 (34–56) | 44 (38–55) | 0.215 |
CRP (mg/L) Median (range) | 2 (0–119.1) | 1.2 (0–32) | 0.025 | 8.1 (0–45.4) | 2.3 (0–29) | 0.063 |
T category a | ||||||
T1 | 6 (27.3%) | 1 (12.5%) | ||||
T2 | 4 (18.2%) | 1 (12.5%) | ||||
T3 | 5 (22.7%) | 3 (37.5%) | ||||
T4 | 7 (31.8%) | 3 (37.5%) | ||||
N category a | ||||||
N0 | 1 (4.5%) | 0 | ||||
N1 | 6 (27.3%) | 3 (37.5%) | ||||
N2 | 12 (54.6%) | 4 (50.0%) | ||||
N3 | 3 (13.6%) | 1 (12.5%) | ||||
Overall stage a | ||||||
I | 1 (4.5%) | 0 | ||||
II | 5 (22.7%) | 2 (25.0%) | ||||
III | 6 (27.3%) | 5 (50.0%) | ||||
IVA-B | 10 (45.5%) | 1 (12.5%) |